LIVER CANCER & PATIENT-DERIVED TUMOUR ORGANOIDS
With
Dr Benjamin Dwyer,
Senior Research Fellow &
Director, Western Australian Organioid Innovation Hub,
Curtin Medical Research Institute,
Curtin University, Western Australia
RESEARCHER PROFILE
Filmed in Perth, Western Australia | February 2026
Dr Benjamin Dwyer is a translational cancer researcher driven by a clear purpose: to ensure discoveries made in the laboratory genuinely improve outcomes for patients.
Based at Curtin University, he established and now leads the organoid platform within the Liver Cancer Collaborative and directs the WA Organoid Innovation Hub, working at the intersection of biology, medicine and biotechnology to accelerate new treatments for liver cancer.
After completing his PhD in Perth, Dr Dwyer joined the world-leading liver research group of Prof Stuart Forbes at the University of Edinburgh, where he contributed to research spanning fundamental biology, clinical trials and commercial translation. He helped define how cholangiocarcinoma crosstalk with macrophages establishes a protective environment. In parallel, he was closely involved in the development of macrophage cell therapy for cirrhosis as part of the management team of the MATCH trials, and established novel, GMP-compatible methods to engineer and cryopreserve therapeutic macrophages, foundational methods for the commercial development of macrophage therapy. He was part of the founding team of a biotechnology spinout created to translate this work, and the therapeutic strategy built on those early methods is now progressing through Phase 1 clinical testing. Seeing principles he helped establish move from bench to bedside has been a defining milestone in his career.
Today, as part of the Liver Cancer Collaborative his research focuses on building patient-derived “mini tumours” for drug development that better predict treatment response, narrowing the gap between laboratory models and real patient outcomes.
COLLABORATIONS WITH:
Perkins Cancer Biobank, Australian Centre for RNA Therapeutics in Cancer, UWA, WA Data Science Innovation Hub, Murdoch University, Epichem, Cholangiocarcinoma Foundation Australia WEHI National Drug Discovery Centre, Inventia Life Sciences, University of Edinburgh, Scottish National Blood Transfusion Service (SNBTS), University of Calgary
FUNDING FROM:
Department of Health WA FHRI Fund, Cancer Research Trust, Gastroenterological Society of Australia (GESA), Ian Potter Foundation, AMMF- The Cholangiocarcinoma Charity,
Source: Supplied and adapted
https://orcid.org/0000-0003-2527-5417
-
Health and economic burden of interstitial lung diseases
Dr Cox’s main research interests focus on respiratory diseases and primarily on the economic burden and economic evaluation of interventions and treatments for their management. She earned her PhD from the University of Tasmania where her doctoral research examined the health and economic burden of idiopathic pulmonary fibrosis (IPF) in Australia, one component of the NHMRC Centre for Research Excellence for Pulmonary Fibrosis, a national project implemented alongside the Australian IPF Registry and the Lung Foundation Australia. This research provided the first epidemiological profile and first costing estimates of the economic burden of the disease in Australia, providing essential evidence for health service reimbursement policies.
-
RESEARCH IMPACT: 32 years of understanding, diagnosing, treating & preventing the onset of heart disease
The Victor Chang Cardiac Research Institute is dedicated to finding cures for cardiovascular disease through world-class and cutting-edge medical research.
The Institute’s team seeks to discover better ways of understanding, diagnosing, treating, and preventing the onset of heart disease. It is committed to ensuring its research breakthroughs are rapidly translated into advances in clinical care.
-
Genetics and Environmental Factors of Glaucoma & Myopia
Professor David Mackey’s original research, over more than 30 years into the genetics of glaucoma and in the fields of optic atrophy and congenital cataract, has received constant professional accolades, attracted ongoing research funding and led to his publication of more than 400 peer-reviewed papers.
